ACTA1 and pulmonary fibrosis: Using a bleomycin-induced pulmonary fibrosis mouse model, the team further observed that L005-B (doses ranging from 0 to 1,000 μg/mL for 48 h) administration significantly reduced fibrotic markers (α-SMA, COL1A1, and fibronectin) while restoring E-cadherin expression in vivo.